Key Highlights

  • Humana (NYSE:HUM) plunged 12.98% on November 18, the steepest decline in the S&P 500, following a 3.88% fall the day before.
  • Over the two sessions the shares shed about 16%, which mirrors how heavily the company leans on Medicare Advantage, the subject of a recent CMS audit plan.
  • CMS would extend audit error rates to whole plan contracts dating back to 2018 and projects recoveries of around USD 90.2 billion through 2036.
  • Publication in the Federal Register is set for November 19, and comment submissions close on January 19, 2027.

Why Humana Took the Heaviest Hit

Humana declined more than any other S&P 500 company on Wednesday, carrying forward a slide that started on Tuesday. The two sessions erased about 16% of its market value. That scale reflects how much of the Business depends on Medicare Advantage, the privately run alternative to traditional Medicare. Many diversified rivals also run large commercial, pharmacy or services arms, whereas Humana draws most of its Revenue from government health plans. Any rule that raises repayment exposure or trims future margins in that segment therefore hits its Earnings harder. Rivals lost ground too, though less steeply: UnitedHealth fell 10.21%, while Elevance Health, Centene and CVS Health retreated 7.63%, 7.03% and 5.20% respectively. Health care as a whole dropped 2.20% on the day. Ardent Health, a hospital operator, slumped sharply after pricing a share sale, adding to the gloom across the industry. Selling was broad and persistent through the session, and buyers showed little interest in stepping in.

What the Proposal Would Do

On November 16, the Centers for Medicare and Medicaid Services proposed recovering more improper payments made to Medicare Advantage plans through audits of risk adjustment data. Sampled members' error rates would, under this design, be projected onto the complete contract, which can swell the amount owed, and the look-back reaches back to 2018 payments. CMS noted that similar 2023 rule provisions were voided on procedural grounds by a court in Texas, and the fresh rulemaking is meant to revive them. Projected collections total roughly USD 90.2 billion across 2027 to 2036, according to the agency. The dispute itself is not new for Humana, which has long opposed extrapolation and was among the challengers of the earlier rule. What has changed is the backdrop: insurers already face higher medical costs and tighter Medicare payment rates, leaving less cushion to absorb repayments. The fresh proposal effectively reopens that fight.

What Could Change the Outlook

A final rule is not expected until after the comment period ends on January 19, 2027, and the industry is expected to lobby for changes. Outcomes could range from a narrower look-back window to a change that factors in coding mistakes in traditional Medicare. Lawsuits are conceivable as well, given how the earlier rule fared. Shareholders will be watching for an estimate of Humana's possible exposure and any statement on whether 2027 plan pricing or benefits could change. Politics matters too. More than half of eligible beneficiaries are now enrolled in Medicare Advantage, and politicians across the aisle have voters relying on these plans, so widespread objections might temper the final version. Against that, officials frame the measure as taxpayer protection, which could make them reluctant to retreat. Until those questions are settled, the shares are likely to stay volatile and responsive to each new headline out of Washington. At minimum, a precise figure from the company would help shareholders measure the downside.

Where Things Stand

Humana was the weakest S&P 500 stock on November 18 as the CMS proposal put its core Medicare Advantage business under threat. Next, watch for any exposure estimate from management and the comment window that ends on January 19, 2027.